

NEIFELD REF.: TACT0010

IN RE: U.S. Patent 6,537,549 of Tobinick

Application serial no. 09/841,844, filed April 25, 2001

FOR: Cytokine antagonists for the treatment of localized disorders

Entity Status: small

**37 CFR 1.7(c) FILING RECEIPT AND TRANSMITTAL LETTER WITH
AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT**

1. THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FEES WHICH MAY BE REQUIRED, OR CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NUMBER 50-2106.

2. FEES PAID HERewith BY EFS CREDIT CARD SUBMISSION: \$70

1.20(d) Statutory disclaimer 70.00 (small entity)

3. **THE FOLLOWING DOCUMENTS ARE SUBMITTED HERewith:**

37 C.F.R. 1.321(a) STATUTORY DISCLAIMER – 1 page

Certification under 37 C.F.R. §3.73(b) – 1 page

4. **FOR INTERNAL NEIFELD IP LAW, PC USE ONLY**

USPTO CHARGES: \$140 CLIENT BILLING MATTER: BANK ACCOUNT/Check: 6/540 G/L ACCOUNT: 5010	FIRM CHARGES: \$300 DESCRIPTION: FIRM CHARGE FOR filing statutory disclaimer. LAWYER: RWH
--	--

INITIALS OF PERSON WHO **ENTERED** ACCOUNTING DATA: RWH

ATTORNEY SIGNATURE (AUTHORIZING DEPOSIT ACCOUNT)

DATE: 12-26-2008

SIGNATURE:/RobertHahl#33,893/

Name: Robert .W. Hahl, Ph.D.

/RichardNeifeld#35,299/

RICHARD NEIFELD REG. NO. 35, 299